Skip to main content

Is this the future of medicine? Synthetic blood could buy patients 48 extra hours

Erythromer, a nanoscale bio-synthetic artificial red cell

Finding blood donors continues to present a challenge across the United States, with hospitals and medical professionals often citing a blood shortage in areas of the country. And while there’s no doubt that we still need folks to visit their local blood drives with hopes of saving a life with their donation, science has stepped in with a new temporary solution. Two scientists — Dr. Andre Palmer of the Ohio State University and Dr. Dipanjan Pan, an associate professor in the department of bioengineering at the University of Illinois — have now independently developed two synthetic blood technologies.

Recommended Videos

Dr. Pan’s product is called ErythroMer, and while it is not, in fact, a blood substitute, it is an “oxygen carrier that can be given as an oxygen-delivery vehicle that can kind of act as a stop-gap measure to keep the injured alive until they get to the hospital,” Pan told Engadget. Essentially, ErythroMer is a manmade hemoglobin — the protein in red blood cells responsible for carrying oxygen to various parts of the body. Because ErythroMer is produced in powder form, it’s capable of being stored for up to six months, which is significantly longer than the shelf life of actual human blood — even when it’s stored properly on ice it can only last up to 42 days. Moreover, because this hemoglobin molecule is artificial, there is a reduced risk of transferring blood-borne diseases like HIV or Zika during transfusions.

As it stands, Pan and his colleagues are hoping to use ErythroMer in military applications, though if successful, the synthetic  blood could doubtless be used in civilian operations as well. Excitingly, NASA has already expressed interest in the synthetic blood, as it may come in handy as astronauts are sent to planets beyond our own.

Meanwhile, Dr. Palmer has created a polymerized hemoglobin, or PolyHb, that is quite similar to Erythromer. It is also based on natural hemoglobin, then encased in a polymer, and is meant “to give the patient enough time to get to a hospital to get a blood transfusion because ultimately, if you lose blood, the best thing you can be transfused with is blood,” as Palmer noted. Again, like Erythromer, PolyHb can be delivered in powdered form, which cuts down on its weight and mass by 50 percent.

This is important as it means that PolyHb is particularly portable, which could be hugely important when treating wounded soldiers on battlefields, or patients in difficult to access areas. All PolyHb needs to be reconstituted is some purified water — then, the powdered platelets can be transfused as needed. PolyHb buys patients up to 48 hours of extra time, which could be the difference between life or death in many medical situations.

While all of these advances are certainly met with excitement by the medical community, there are, of course, still shortcomings. Currently, neither ErythroMer nor PolyHb can do more than transport oxygen — while this is a major function of blood, it’s not the only function, which means  that you couldn’t replace your entire bloodstream with these synthetic solutions.

As Palmer told Engadget, “You’d have the oxygen-carrying therapeutic, and then you’d have something that initiates clotting, for example. So it is possible to mix two different therapeutics together to achieve extra functions.” We’re just waiting on that possibility to become a reality.

Lulu Chang
Former Digital Trends Contributor
Fascinated by the effects of technology on human interaction, Lulu believes that if her parents can use your new app…
Range Rover’s first electric SUV has 48,000 pre-orders
Land Rover Range Rover Velar SVAutobiography Dynamic Edition

Range Rover, the brand made famous for its British-styled, luxury, all-terrain SUVs, is keen to show it means business about going electric.

And, according to the most recent investor presentation by parent company JLR, that’s all because Range Rover fans are showing the way. Not only was demand for Range Rover’s hybrid vehicles up 29% in the last six months, but customers are buying hybrids “as a stepping stone towards battery electric vehicles,” the company says.

Read more
BYD’s cheap EVs might remain out of Canada too
BYD Han

With Chinese-made electric vehicles facing stiff tariffs in both Europe and America, a stirring question for EV drivers has started to arise: Can the race to make EVs more affordable continue if the world leader is kept out of the race?

China’s BYD, recognized as a global leader in terms of affordability, had to backtrack on plans to reach the U.S. market after the Biden administration in May imposed 100% tariffs on EVs made in China.

Read more
Tesla posts exaggerate self-driving capacity, safety regulators say
Beta of Tesla's FSD in a car.

The National Highway Traffic Safety Administration (NHTSA) is concerned that Tesla’s use of social media and its website makes false promises about the automaker’s full-self driving (FSD) software.
The warning dates back from May, but was made public in an email to Tesla released on November 8.
The NHTSA opened an investigation in October into 2.4 million Tesla vehicles equipped with the FSD software, following three reported collisions and a fatal crash. The investigation centers on FSD’s ability to perform in “relatively common” reduced visibility conditions, such as sun glare, fog, and airborne dust.
In these instances, it appears that “the driver may not be aware that he or she is responsible” to make appropriate operational selections, or “fully understand” the nuances of the system, NHTSA said.
Meanwhile, “Tesla’s X (Twitter) account has reposted or endorsed postings that exhibit disengaged driver behavior,” Gregory Magno, the NHTSA’s vehicle defects chief investigator, wrote to Tesla in an email.
The postings, which included reposted YouTube videos, may encourage viewers to see FSD-supervised as a “Robotaxi” instead of a partially automated, driver-assist system that requires “persistent attention and intermittent intervention by the driver,” Magno said.
In one of a number of Tesla posts on X, the social media platform owned by Tesla CEO Elon Musk, a driver was seen using FSD to reach a hospital while undergoing a heart attack. In another post, a driver said he had used FSD for a 50-minute ride home. Meanwhile, third-party comments on the posts promoted the advantages of using FSD while under the influence of alcohol or when tired, NHTSA said.
Tesla’s official website also promotes conflicting messaging on the capabilities of the FSD software, the regulator said.
NHTSA has requested that Tesla revisit its communications to ensure its messaging remains consistent with FSD’s approved instructions, namely that the software provides only a driver assist/support system requiring drivers to remain vigilant and maintain constant readiness to intervene in driving.
Tesla last month unveiled the Cybercab, an autonomous-driving EV with no steering wheel or pedals. The vehicle has been promoted as a robotaxi, a self-driving vehicle operated as part of a ride-paying service, such as the one already offered by Alphabet-owned Waymo.
But Tesla’s self-driving technology has remained under the scrutiny of regulators. FSD relies on multiple onboard cameras to feed machine-learning models that, in turn, help the car make decisions based on what it sees.
Meanwhile, Waymo’s technology relies on premapped roads, sensors, cameras, radar, and lidar (a laser-light radar), which might be very costly, but has met the approval of safety regulators.

Read more